Benchtalk 2025: Benchling Co-Founder & CEO Sajith Wickramasekara describes why he believes science and Benchling are entering a new era of speed and cost of R&D

blonca9
Oct 14
1 min read

He welcomes us to Benchtalk 2025, which had more than 800 scientists register this year, and describes how AI and other computational advances are allowing scientists to focus on increasing the speed and reducing the cost of R&D.

Coverage brought to you by

Recent Posts

See All

From London: Cancer Research Horizons takes research from Cancer Research UK (and beyond) and invests in the translational work and companies that turn it into cures

Jefferies London: Affinity Asset Advisors' Patrick Nosker shares a public investor's perspective on biotech and comments on a few of his firm's top positions

Jefferies London: Medicxi announced a €500 million Fund V ahead of this week's conference - Co-founder Giovanni Mariggi describes the firm's asset-centric approach to investing in biotech

Benchtalk 2025: Benchling Co-Founder & CEO Sajith Wickramasekara describes why he believes science and Benchling are entering a new era of speed and cost of R&D

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight